We are live on
!
Find out more
LPC
Lion Point Capital Portfolio holdings
AUM
$16.7M
1-Year Est. Return
119.35%
This Fund
S&P 500
This Quarter
Est. Return
+8.17%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$54.9M
AUM Growth
-$124M
(-69%)
Cap. Flow
-$104M
Cap. Flow
% of AUM
-189.39%
Top 10 Holdings %
Top 10 Hldgs %
82.94%
Holding
32
New
1
Increased
5
Reduced
6
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BridgeBio Pharma
BBIO
|
+$1.34M |
| 2 |
Mineralys Therapeutics
MLYS
|
+$239K |
| 3 |
Geron
GERN
|
+$117K |
| 4 |
Neurocrine Biosciences
NBIX
|
+$117K |
| 5 |
Milestone Pharmaceuticals
MIST
|
+$64.3K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ardelyx
ARDX
|
+$1.34M |
| 2 |
Humacyte
HUMA
|
+$731K |
| 3 |
Travere Therapeutics
TVTX
|
+$601K |
| 4 |
Kiniksa Pharmaceuticals
KNSA
|
+$487K |
| 5 |
Replimune Group
REPL
|
+$347K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.93% |
| 2 | Financials | 1.56% |
| 3 | Consumer Discretionary | 1.02% |
| 4 | Technology | 0.08% |
| 5 | Energy | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Battalion Oil
BATL
$28.2M
| $24.8K | 0.05% |
7,423
-12,503
| -63% | -$66.8K |
|
27
Alphabet (Google) Class C
GOOG
$4.07T
| $18.3K | 0.03% |
100
| – | – |
|
|
28
Humacyte
HUMA
$170M
| – | – |
-235,000
| Closed | -$731K |
|
|
29
Replimune Group
REPL
$449M
| – | – |
-42,500
| Closed | -$347K |
|
30
CALL
Semtech
SMTC
$10.4B
| – | – |
-2,500,000
| Closed | -$68.7M |
|
|
31
Semtech
SMTC
$10.4B
| – | – |
-14
| Closed | -$385 |
|
|
32
Travere Therapeutics
TVTX
$5.2B
| – | – |
-78,000
| Closed | -$601K |
|
Similar funds
PA
SR
SCTC
SRA
CP
B
CVV
BCPE
Lion Point Capital's Q2 2024 Portfolio in Review
As of Q2 2024, Lion Point Capital held 32 positions worth $54.9M, down 69% from $179M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Lion Point Capital withdrew a net $104M in Q2 2024, closing 5 positions and reducing 6 holdings. Its most notable exit was Humacyte, an estimated $731K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 17% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Lion Point Capital opened a new position in BridgeBio Pharma worth $1.24M.
- Lion Point Capital's largest Q2 2024 buy was BridgeBio Pharma: 49,000 shares worth $1.24M.
- Lion Point Capital added most to Mineralys Therapeutics in Q2 2024, an estimated $239K increase.
- Lion Point Capital's biggest Q2 2024 reduction was Ardelyx, cutting an estimated $1.34M.
- Lion Point Capital fully exited Humacyte in Q2 2024, selling an estimated $731K.
- Lion Point Capital's ten largest holdings make up 83% of its $54.9M portfolio in Q2 2024.
- Lion Point Capital opened 1 new position and closed 5 in Q2 2024.
- Lion Point Capital's portfolio value fell 69% quarter-over-quarter to $54.9M.
Based on Lion Point Capital's 13F filing for Q2 2024, filed 14 Aug 2024.